Kornimate/medical-research-clean huggingface dataset:
use of new generation fetoscopes in pregnancies affected by fetal diseases amenable to fetoscopy therapy

Conditions: In Utero Procedure Affecting Fetus or Newborn

Summary: the researchers are trying to determine feasibility and safety of performing surgery in the womb with the karl storz fetoscopes (a tool used to access the baby in the body of the mother). this are new and improved fetoscopes that are not yet approved by the fda.


Eligibility criteria:
inclusion criteria: * patient is a pregnant woman 18 and older * the mother must be healthy enough to have surgery * the mother must be scheduled for surgery * patient provides signed informed consent that details the maternal and fetal risks involved with the procedure exclusion criteria: * age \<18 years * contraindication to abdominal surgery, fetoscopic surgery, or general anesthesia * preterm labor, preeclampsia, or uterine anomaly (e.g., large fibroid tumor) in the index pregnancy. * fetal aneuploidy, any significant pathogenic or likely significant pathogenic findings on karyotype or microarray (if available, but not required), other major fetal anomalies that impacts significantly the fetal/neonatal survival.

Keywords: fetoscopes
application of multi-probe pet/mr imaging in the diagnosis and evaluation of alzheimer's disease

Conditions: Alzheimer Disease; PET/MR

Summary: alzheimer's disease (ad) is the most common cause of cognitive impairment, and its diagnosis requires a comprehensive analysis of the results of medical history, neuropsychological evaluation, imaging and laboratory tests. among them, it has been widely recognized that amyloid pet imaging is used in the early diagnosis of ad, tau protein pet imaging is used in the assessment of the progression of ad, and the glucose metabolism pet imaging is used in the assessment of nerve damage. mri can provide structure, blood perfusion, neural network connection damage and other information through multi-sequence scans. with the help of the pet/mr multi-modal imaging platform and multi-probe imaging technology, it can provide more sensitive and accurate imaging information for early diagnosis and disease assessment of ad, and provide a basis for clinical treatment decision-making.

cognitive impairment is a common neurodegenerative disease. the incidence of alzheimer's disease (ad) in people over 65 years old is close to 5%, which brings a heavy burden to society. relying only on medical history and neuropsychological evaluation, the early diagnosis and differential diagnosis of ad are difficult, and further imaging and laboratory tests are needed. this project will use pet/mri, the most advanced imaging platform, to design a prospective clinical research program, combined with multi-sequence mri and multi-probe pet imaging, to evaluate suspected or diagnosed ad patients. through multi-parameter analysis of the structure mri, function mri (3d asl, bold, dti), metabolism pet (18f-fdg) , aβ (11c-pib) and tau (18f-pm-pbb3) pet, combined with clinical information, to evaluate the value of multi-modal imaging for early diagnosis and differential diagnosis of ad, to assist the clinic in the adjustment of early intervention measures and treatment strategies.

Eligibility criteria:
inclusion criteria: * patients who meet the core clinical diagnostic criteria for alzheimer's disease as defined by nia-aa for mild cognitive decline or probable alzheimer's disease. * subjects are able to understand and sign the informed consent voluntarily, with good compliance. exclusion criteria: * have contraindications to pet/mr examination. * clinically clear history of stroke. * have a history of bipolar disorder or depression. * patients with severe heart, liver, and kidney dysfunction. * pregnant or lactating women. * patients refuse to sign the informed consent.
embryonic ploidy status in the oncofertility population

Conditions: Oncology; Fertility

Summary: looking at aneuploidy rates in embryos from patients who are going to or have undergone treatment for a malignancy with gonadotoxic treatment.

the study involves oncofertility patients--individuals who are undergoing or have undergone therapy for a malignancy--who are interested in pursuing or preserving fertility. in particular, it investigates chromosomal abnormalities or aneuploidy in the embryos of those individuals as compared to the general infertility population. embryonic aneuploidy is largely due to reproductive senescence. as such the investigators will discuss oncofertility prevalence and treatment as well as reproductive senescence and assessment of embryonic aneuploidy. the study will seek to determine if there are changes in embryonic aneuploidy rates in oncofertility patients that differ from simple age related risks.

Eligibility criteria:
inclusion criteria: 1.present or past oncologic diagnosis requiring potentially gonadotoxic treatment exclusion criteria: 1. oocyte banking 2. use of oocyte donation 3. any contraindications to undergoing in vitro fertilization or gonadotropin stimulation 4. single gene disorder requiring more detailed embryo genetic analysis
a study of the effect of ro4917838 on biomarker measures of cognitive dysfunction in participants with schizophrenia and schizoaffective disorder

Conditions: Schizophrenia

Summary: this randomized, double-blind, placebo-controlled parallel group study will assess the effect on biomarkers measures of cognitive dysfunction, the clinical efficacy and safety of ro4917838 in participants with schizophrenia and schizoaffective disorder. participants will be randomized to receive either ro4917838 (10 milligrams \[mg\] daily orally) or placebo for 6 weeks, in addition to their stable antipsychotic medication. anticipated time on study treatment is 6 weeks.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder (based on screening tests) * medically stable for 1 month and psychiatrically stable without symptom exacerbation for 6 weeks prior to baseline * on stable treatment with a maximum of 2 antipsychotics exclusion criteria: * change in regimen for any psychotropic or sleep medication within 1 month * treatment with more than (\>) 1 mood stabilizer or antidepressant * use of clozapine within 2 months * bipolar disorder, or more than mild anxiety disorder
post-marketing surveillance (pms) study to observe the safety and effectiveness of arnuity in asthma subjects in a real world setting

Conditions: Asthma

Summary: this is an open-label, multi-center, pms study to observe the safety and effectiveness of arnuity administered in asthma subjects in a real world setting. this pms shall observe how a broad range of subjects use the drug in the early stages after obtaining the approval. the objective of this pms is to collect safety and effectiveness data on arnuity's approved label in a real world setting. total of 600 subjects shall be recruited throughout the pms period; 01 sep, 2018 to 30 june 2020. arnuity is the registered trademark of gsk group of companies.


Eligibility criteria:
inclusion criteria: * pediatric subjects older than 12 years of age and adult subjects with asthma * subjects who will administer arnuity in accordance with the product information approved in korea * subjects who have signed the informed consent form for the pms exclusion criteria: * subjects with status asthmaticus or subjects who have administered arnuity as primary therapy for other acute asthmatic episodes that require intensive treatment * subjects who have any known hyper-sensitivity to the drug or its ingredients * subjects who have severe hypersensitive reactions to milk proteins * subjects with hereditary problems of galactose intolerance, the lapp lactase deficiency, or glucose-galactose malabsorption

Keywords: arnuity effectiveness asthma post-marketing surveillance safety
respiratory tract microbiome and probiotics in children with cleft palate

Conditions: Otitis Media in Children; Cleft Palate Children

Summary: otitis media with effusion (ome) involves fluid accumulation in the middle ear without infection, sometimes causing discomfort and hearing loss in children. persistent middle ear fluid lasting over 3 months may require treatment, including placement of ventilation tubes if it affects hearing. children with a cleft palate are at higher risk for otorrea after ventilation tube placement. treatment typically involves antibiotic drops and ear cleaning by an ent doctor, often requiring repeated visits, which may impact quality of life for both the child and the parents. the mouth, throat, and nose harbor bacteria that can influence ear infections. this study aims to determine if probiotics can alter the bacteria in the nasopharynx and middle ear fluid and reduce the number of episodes of eardischarge following ventilation tube placement in children with cleft palate. using lacticaseibacillus rhamnosus gg and bifidobacterium lactis bb-12 from bactiol® baby (metagenics), patients will be divided into two groups: one receiving probiotic drops and one not. the study will assess if probiotics can reduce the number of episodes with ear discharge in children with cleft palate, by examining the following: 1. the airway microbiome composition in children with cleft palates. 2. whether oral probiotics can reduce the number and duration of ear discharge episodes.


Eligibility criteria:
inclusion criteria: * cleft palate \& lip (uni/bilateral) or cleft palate * no syndromal disorders exclusion criteria: * syndromal disorder * history of ventilation tube placement

Keywords: otitis media upper respiratory tract microbiome cleft palate probiotics lacticaseibacillus rhamnosus gg
restylane-l for correction of infraorbital hollows

Conditions: Infraorbital Hollows

Summary: this is a prospective, randomized, evaluator-blinded, no-treatment controlled, parallel group, multi-center us study to evaluate the safety and effectiveness of restylane-l® for correction of infraorbital hollows.


Eligibility criteria:
inclusion criteria: * moderate or severe infraorbital hollows with no more than one grade difference between the left and right side at baseline as assessed by the blinded evaluator. * males or non-pregnant, non-breastfeeding females, over the age of 21. * intent to undergo correction of both orbital hollows. exclusion criteria: * known/previous allergy or hypersensitivity to any injectable hyaluronic acid (ha) gel or to gram positive bacterial proteins. * known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics. * previous deep and/or superficial facial dermal therapies. * active or a history of recurrent or chronic infraorbital edema or rosacea or uncontrolled severe seasonal allergies.

Keywords: tear trough
nocturnal breathing and sleep in patients with chronic obstructive pulmonary disease staying at altitude

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to evaluate whether nocturnal breathing and sleep of patients with chronic obstructive pulmonary disease (copd) are disturbed during a stay at moderate altitude.

this randomized cross-over trial evaluates the hypothesis that patients with chronic obstructive pulmonary disease experience nocturnal hypoxemia, periodic breathing and sleep disturbances when staying at moderate altitude. sleep studies and clinical evaluations will be performed during 2 days in zurich (490 m, low altitude baseline) and during 2 days at davos clavadel (1650 m), and 2 days at davos jakobshorn (2590 m).

Eligibility criteria:
inclusion criteria: * chronic obstructive pulmonary disease (copd), gold grade 2-3 * residents at low altitude (\<800 m) exclusion criteria: * unstable condition, copd exacerbation * mild (gold 1) or very severe copd (gold 4) * requirement for oxygen therapy at low altitude residence * hypoventilation * pulmonary hypertension * more than mild or unstable cardiovascular disease * use of drugs that affect respiratory center drive * internal, neurologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day), inability to perform 6 min walk test. * previous intolerance to moderate altitude (\<2600m). * exposure to altitudes \>1500m for \>2 days within the last 4 weeks before the study. * pregnant or nursing patients
telerehabilitation exercise: effects on maternal psychological health and delivery outcomes

Conditions: Gestational Diabetes Mellitus in Pregnancy; Gestational Diabetes; Maternal Psychological Distress

Summary: gestational diabetes occurs when the body can't make enough insulin to manage high blood sugar during pregnancy, usually developing between the 24th and 28th weeks. it affects about 14% of pregnancies worldwide. women with gestational diabetes often feel more anxious and stressed and have a higher risk of depression during and after pregnancy. this study will explore how telerehabilitation can reduce anxiety and depression and show how exercise can improve the health of pregnant women with gestational diabetes.

the diagnosis of gdm can be unexpected and distressing, leading to feelings of sadness and hopelessness.women with gdm are at a higher risk of experiencing prenatal and postnatal depression, which can affect their overall well-being and ability to care for their newborn. regularly checking blood sugar levels, changing diet, and possibly using medication or insulin can be overwhelming. this constant effort and worry about complications can cause a lot of anxiety and stress. many pregnant women with gdm might not fully understand how exercise can help control their blood sugar levels and improve their overall well-being. developing a positive attitude towards exercise is important for helping people with gestational diabetes manage their condition effectively through physical activity. the use of telerehabilitation may improve psychological symptoms in participants with gdm. the control group will receive routine medical care and the experimental group will receive structured telerehabilitation exercise protocol. the results of both groups will be recorded and compared to assess the effectiveness of using telerehabilitation in the treatment of women with gdm in improving psychological health.

Eligibility criteria:
inclusion criteria: * women aged 20 to 35 years * gestational age between 20-28weeks * diagnosed with gestational diabetes mellitus through oral glucose tolerance test (ogtt) * primigravida and multigravida * able to do 6 6-minute walk tests under a severity level of 6 on the borg scale of breathlessness. * patients or caregivers have and able to use an electronic device (pc, tablet or smartphone) * who signed informed consent exclusion criteria: * previously diagnosed t1dm or t2dm * high-risk pregnancy conditions contraindicating exercise as per acog guidelines * patients taking insulin regularly. * patients with fetal anomalies diagnosed at 20 th week. * multiple gestation (twin or triplets).
application of tracheal intubation in lateral position in thoracic surgery

Conditions: Anesthesia; Tracheal Intubation; Thoracic Surgery

Summary: this study investigated the incidence of bronchial blocker malposition in the lateral versus supine position and evaluated the effectiveness of lateral placement.

routine thoracic surgery anesthesia requires that endotracheal intubation be performed with the patient in the supine position; the patient subsequently needs to be placed in a lateral position through the cooperation of the anesthetist, theatre nurse, and surgeon. achieving this change in position is time-consuming and likely to result in adverse events, such as loss of the anesthetic airway and arteriovenous catheter, hemodynamic fluctuations, and malposition of the bb which adversely affect anesthesia management and postoperative recovery. for patients with hypertensive heart disease, the risk of cardiovascular and cerebrovascular accidents increases during the perioperative period . therefore, we conducted a prospective, randomized, controlled, multi-center study to evaluate the ease, efficacy, and safety of video laryngoscopy-guided intubation and bronchial blocker placement performed in lateral position.

Eligibility criteria:
the inclusion criteria : * 80 years\<age ≥18 years; * american society of anesthesiologists (asa) physical status i-iii; * undergo thoracic surgery requiring one-lung ventilation. the exclusion criteria were: * risk of difficult intubation based on preoperative assessment (maximum mouth opening \ 30 kg/m2, limited neck movement, mallampati grade iv, or main airway stenosis); * right upper bronchus originating at or above the tracheal carina; * plan to undergo bronchial sleeve resection, right upper lobectomy, or non-intubated thoracic surgery; * evidence or symptoms of acute lung or airway infection; * history of thoracic surgery; * prior thoracic radiotherapy or chemotherapy; * preoperative upper extremity pain; * severe mental illness or difficulty with communication.

Keywords: lateral position bronchial occluder
vax-mom covid-19: increasing maternal covid-19 vaccination

Conditions: Immunization; Infection; Pregnancy Related; COVID-19

Summary: covid-19 infection during pregnancy is associated with increased risk of pre-eclampsia, preterm birth and stillbirth. pregnant people with covid-19 have a higher rate of icu admission and intubation than those who are not pregnant. covid-19 vaccine is recommended before pregnancy and during pregnancy to decrease these risks. despite the benefits of covid-19 vaccination, only 71% of pregnant women were vaccinated for covid-19 as of june 2022 (most prior to pregnancy), with a much lower rate of 58% among non-hispanic black women. an effective intervention is needed to improve covid vaccination rates for pregnant people overall. in this study, the investigators will perform a randomized controlled trial aimed at practice change in obstetricians' offices, with an overall goal of increasing maternal covid-19 vaccination rates.

covid-19 infection during pregnancy is associated with increased risk of pre-eclampsia, preterm birth and stillbirth. pregnant people with covid-19 have a higher rate of icu admission and intubation than those who are not pregnant. covid-19 vaccine is recommended before pregnancy and during pregnancy to decrease these risks. despite the benefits of covid-19 vaccination, only 71% of pregnant women were vaccinated for covid-19 as of june 2022 (most prior to pregnancy), with a much lower rate of 58% among non-hispanic black women. an effective intervention is needed to improve covid-19 vaccination rates for pregnant people overall. lack of vaccination stems from a combination of patient (lack of knowledge, vaccine hesitancy), provider (suboptimal communication skills, missed opportunities), and system (e.g. lack of standing orders and patient reminders) factors. an effective intervention is needed to improve covid-19 vaccination rates for pregnant people. to address this, the investigators plan to use a clustered rct (randomizing practices), allocating half of the participating practice sites within each health system to the vax-mom covid-19 intervention and the other half to standard of care. the multi-component vax-mom covid-19 intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.

Eligibility criteria:
inclusion criteria: patient criteria: * sex is female * pregnant * identified as being eligible for covid-19 vaccine practice personnel criteria: \*provider, nurse or staff currently affiliated with (employed with) the participating ob/gyn sites exclusion criteria: \*none

Keywords: covid-19 vaccination prenatal care
input of a multidisciplinary device to accompany the announce of diagnosis for young children with serious constitutional hemorrhagic disease and their families

Conditions: Severe Forms of Hemophilia; Other Constitutional Bleeding Disorders

Summary: severe forms of hemophilia and other constitutional bleeding disorders represent a group of rare diseases. in last decades, news therapies have dramatically increased life expectancy and joint's protection. the investigators propose to set up a single-centre, descriptive, transversal pilot study, designed for the inclusion of around thirty children from 2 to 10 years, with haemophilia or allied hereditary bleeding disorders (hbd), who were referred to the hemophilia treatment center (htc) of marseille at diagnosis. for those children who were able to benefit from the totality or part of the device accompanying the diagnostic announcement in the past 10 years.

severe forms of hemophilia and other constitutional bleeding disorders represent a group of rare diseases. in last decades, news therapies have dramatically increased life expectancy and joint's protection. the recurrence of joint bleedings is responsive of multifocal arthropathy in the natural history, but nowadays, the orthopedic outcome is good thanks to prophylactic treatments. however, the announcement of the diagnosis of such hereditary bleeding disorders at a very young age represents a real psychological trauma for parents. such an announcement may induce some psycho-developmental impairment. an innovative support has been implemented at the hemophilia treatment center in marseille, in conjunction with the french hemophilia society. this program is based on a multidisciplinary partnership that favors the psychological support and the reinsurance of the parents. with rare diseases foundation support, the investigators have initiated this pilot study that will include more than 20 patients with severe hemophilia or constitutional bleeding disorder, who benefit from the device. this descriptive, monocentric, interventional study will permit to describe the psychological status, the quality of life of patients and their parents, but also to evaluate the impact of the device on initiation and observance of treatments like long term prophylaxis.

Eligibility criteria:
inclusion criteria: * patients aged between 3 and 12 years * patients diagnosed and treated at the center until inclusion * patients with fviii :c \< 2% or with fix :c \<2% or with fvii:c \<2% or with fxiii:c \<2% or fibrinogen \<0,2 g/l, or with type 3 von willebrand diseases or thrombasthenia of glanzmann diseases. * patient who participate to multidisciplinary support and announcement of diagnosis device * voluntarily given fully informed written and signed consents obtained before any study-related procedures are conducted exclusion criteria: * patient with other clotting disorder or disease. * patient diagnosed or treated in other centre * patient with psychiatric disorder or disease * patient with other severe chronic disease